Tuesday, May 11, 2021 Daily Archives

COVID-19 expansions drive confidence at Maravai

by

Maravai LifeSciences highlighted expansions at customers Pfizer and BioNTech as indicators that demand for mRNA capping solutions will continue to grow. Maravai attained its messenger RNA (mRNA) capping solution, called CleanCap, through the acquisition of contract development and manufacturing organization (CDMO) TriLink BioTechnologies in 2016. In its first quarter 2021, the firm reported $91 million in CleanCap revenue, an increase of 76% when compared to Q4 2020. Going forward the firm “expect continued strong demand from our existing COVID-19 CleanCap…

May 11, 2021

Laronde aims to turn cells into drug production facilities using eRNA

by

Venture capital backed biotech Laronde has created a new type of RNA it claims can be used to create programmable protein therapeutics. The Massachusetts based firm unveiled its “Endless RNA†platform this week, while also confirming it had secured a $50 million investment to support development and an initial pipeline of medicines from Flagship Pioneering. Endless RNA – or eRNA – is based on of long non-coding RNA (lncRNA), which is naturally abundant in circular form within mammalian cells. Unlike…

May 11, 2021

Podcast: On board the Cell Shuttle with Cellares

by

Cellares Corporation’s CEO Fabian Gerlinghaus talks about the current limitations in cell therapy production and how, with $82 million in hand, its Cell Shuttle technology could resolve these. Tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle. Having raised $82 million in its latest funding round, co-founder and CEO Fabian Gerlinghaus spoke about how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space on…

May 11, 2021

Richter-Helm to triple biologics capacity through €70m investment

by

German CDMO Richter-Helm will install both stainless-steel and single-use technologies at a new facility at its Bovenau site, increasing total biomanufacturing capacity three-fold. Self-proclaimed mid-sized contract development and manufacturing organization (CDMO) Richter-Helm has facilities in Hannover and Bovenau, Germany, with bioreactor capacities of up to 1,500 liters. But the CDMO is looking to benefit from continuous growth in demand for biomanufacturing capacity and services, and on May 5 broke ground on a new €70 million ($85 million) at the Bovenau…

May 11, 2021